Celldex Therapeutics, Inc. (CLDX) P/S ratio
Celldex Therapeutics, Inc. (CLDX) trades at 1205.5× its revenue per share for fiscal 2025. At the end of fiscal 2024 (December 31, 2024) its P/S ratio was 231.8×. That is 17.0% lower than the 279.2× of fiscal 2023. Figures as of 18 Nov 2026, 02:34 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/S ratio today
- 1205.5×
- P/S ratio, fiscal 2024
- 231.8×
- Change on fiscal 2023
- −17.0%
- Highest on record
- 279.2×fiscal 2023
- Lowest on record
- 0.0×fiscal 2019
- Fiscal years on record
- 82009–2024
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Celldex Therapeutics, Inc. P/S ratio, in more detail
Today's figure is 420.0% above the fiscal 2024 year-end.
Across the 8 fiscal year-ends on record (2009–2024), the highest was 279.2× in fiscal 2023 and the lowest 0.0× in fiscal 2019. Today's P/S ratio is above every one of the 8 fiscal year-ends on record; their median is 4.5×.
P/S ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Celldex Therapeutics, Inc. P/S ratio, year by year
| Fiscal year | P/S ratio | Change | Year ended | Share price at year-end | Revenue per share |
|---|---|---|---|---|---|
| Today | 1205.5× | — | $28.04 | — | |
| 2025 | — | — | $27.16 | $0.02 | |
| 2024 | 231.8× | 17.0% down | $25.27 | $0.11 | |
| 2023 | 279.2× | — | $39.66 | $0.14 | |
| 2022 | — | — | $44.57 | $0.05 | |
| 2021 | 0.4× | 408.8% up | $38.64 | $108.49 | |
| 2020 | 0.1× | 673.2% up | $17.52 | $250.27 | |
| 2019 | 0.0× | — | $2.23 | $246.29 | |
| 2018 | — | — | $3.00 | — | |
| 2017 | — | — | $42.60 | — | |
| 2016 | — | — | $53.10 | — | |
| 2015 | — | — | $235.20 | — | |
| 2014 | — | — | $273.75 | — | |
| 2013 | — | — | $363.15 | — | |
| 2012 | — | — | $100.65 | — | |
| 2011 | 11.1× | 295.1% up | $39.00 | $3.52 | |
| 2010 | 2.8× | 54.0% down | $61.80 | $22.03 | |
| 2009 | 6.1× | — | $70.05 | $11.49 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
How to read it
It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.
Celldex Therapeutics, Inc., figure by figure
- Celldex Therapeutics, Inc. market cap
- Celldex Therapeutics, Inc. revenue
- Celldex Therapeutics, Inc. earnings
- Celldex Therapeutics, Inc. earnings per share (EPS)
- Celldex Therapeutics, Inc. P/E ratio
- Celldex Therapeutics, Inc. P/B ratio
- Celldex Therapeutics, Inc. free cash flow
- Celldex Therapeutics, Inc. operating margin
- Celldex Therapeutics, Inc. dividend
- Celldex Therapeutics, Inc. shares outstanding
- Celldex Therapeutics, Inc. total debt
- Celldex Therapeutics, Inc. cash on hand
- Celldex Therapeutics, Inc. total assets
- Celldex Therapeutics, Inc. return on equity (ROE)
- Celldex Therapeutics, Inc. return on invested capital (ROIC)
Celldex Therapeutics, Inc. (CLDX) overview: price, valuation and scorecard
Celldex Therapeutics, Inc. P/S ratio: questions and answers
What is Celldex Therapeutics, Inc.'s P/S ratio?
Celldex Therapeutics, Inc. (CLDX) trades at 1205.5× its revenue per share for fiscal 2025. At the end of fiscal 2024 (December 31, 2024) its P/S ratio was 231.8×. That is 17.0% lower than the 279.2× of fiscal 2023.
Is Celldex Therapeutics, Inc.'s P/S ratio high or low compared with its own history?
Today's P/S ratio is above every one of the 8 fiscal year-ends on record; their median is 4.5×.
What are the highest and lowest P/S ratio figures on record for Celldex Therapeutics, Inc.?
Across the 8 fiscal year-ends on record (2009–2024), the highest was 279.2× in fiscal 2023 and the lowest 0.0× in fiscal 2019.
How is Celldex Therapeutics, Inc.'s P/S ratio calculated?
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/S ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Celldex Therapeutics, Inc. (CLDX) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/CLDX/ps-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.